Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CPS Clear all
Completed No phase listed Observational

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

NCT06771674
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma
Interventions
Pembrolizumab, Nivolumab
Drug
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years and older
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 7, 2026, 5:43 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

NCT07762703
View directory record Official record
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin
Drug
Lead sponsor
BreakBio Corp
Industry
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 7, 2026, 5:43 AM EDT
Recruiting Not applicable Interventional

Combining a Smartphone App With Medications to Manage Heavy Drinking

NCT06303778
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Stand Down mobile app, Standard Care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 7, 2026, 5:43 AM EDT
Recruiting No phase listed Observational

Childhood Cancer Predisposition Study (CCPS)

NCT04511806
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Registry
Other
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 7, 2026, 5:43 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

NCT06295731
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
INBRX-106, Pembrolizumab
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
25
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 7, 2026, 5:43 AM EDT
Completed Not applicable Interventional

Improving Surgical/Medical Oncology Collaboration for Breast Cancer Treatment Planning: Pilot Testing the Impact of Continuing Education and Patient Care Planning

NCT03161600
View directory record Official record
Conditions
Breast Cancer
Interventions
Carevive CPS
Behavioral
Lead sponsor
Carevive Systems, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 7, 2026, 5:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer

NCT03304132
View directory record Official record
Conditions
Oral Cancer
Interventions
Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach, Classification of Oral Microbiome Using taxonomic approach
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 92 Years
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Sep 7, 2026, 5:43 AM EDT
Not yet recruiting Not applicable Interventional

The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study

NCT07216963
View directory record Official record
Conditions
Opioid Use Disorder, Overdose, Drug, Overdose, Substance Use (Drugs, Alcohol)
Interventions
Community Paramedic Standard of Care (CP SOC), CROSSROADS
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 7, 2026, 5:43 AM EDT
Completed No phase listed Observational

Executive Function and Symptom Reduction in Youth Receiving Home-based Treatment With Collaborative Problem Solving

NCT04121650
View directory record Official record
Conditions
Child Behavior, Problem Behavior, Executive Dysfunction
Interventions
Collaborative Problem Solving
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 14 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 7, 2026, 5:43 AM EDT
Completed Not applicable Interventional Results available

EHR Embedded Comparative Effectiveness Studies--CPS

NCT04520009
View directory record Official record
Conditions
Disk Herniated Lumbar
Interventions
Activity Restriction, Activity as Tolerated
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Sep 7, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast

NCT00671411
View directory record Official record
Conditions
Renal Cancer, Kidney Cancer
Interventions
Ultrasound with intravenous microbubble contrast injection
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced Sep 7, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

NCT05104567
View directory record Official record
Conditions
Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Oesophageal Adenocarcinoma
Interventions
THOR-707, Pembrolizumab, Cetuximab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Duarte, California • Orlando, Florida • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 7, 2026, 5:43 AM EDT
Suspended Not applicable Interventional

A Study to Improve Diabetes Management Among Adults Experiencing Severe Hypoglycemia

NCT04874532
View directory record Official record
Conditions
Diabetes, Hypoglycemia, Diabetes Type 1, Diabetes Type 2
Interventions
Community Paramedic Program, Education Material
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 7, 2026, 5:43 AM EDT
Completed Phase 1 Interventional Results available

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

NCT04047862
View directory record Official record
Conditions
Locally Advanced and Metastatic Solid Tumors
Interventions
Ociperlimab, Tislelizumab, Pemetrexed, Paclitaxel, Nab paclitaxel, Carboplatin, Cisplatin, Etoposide, 5fluorouracil, Oxaliplatin, Capecitabine
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
11
States / cities
Phoenix, Arizona • Fort Myers, Florida • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 7, 2026, 5:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy and Sustainability of a Carepartner-Integrated Telerehabilitation Program for Persons With Stroke

NCT06655402
View directory record Official record
Conditions
Stroke, Caregiver Burden
Interventions
CARE-CITE, Attention Control Group, Actigraph GT3X+
Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 7, 2026, 5:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families

NCT05000632
View directory record Official record
Conditions
Child Maltreatment, Smoking Behaviors
Interventions
Smoke Free SafeCare, Standard SafeCare
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
18 Years to 89 Years
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 7, 2026, 5:43 AM EDT
Completed Not applicable Interventional

Physician Awareness of Patients' Preferred Level of Involvement in Decision Making

NCT05314959
View directory record Official record
Conditions
Preferred Level of Involvement in Decision Making
Interventions
Physician Awareness, Usual Care
Other
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 7, 2026, 5:43 AM EDT
Terminated Not applicable Interventional

Decision Support for Women With Breast Cancer

NCT01447771
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Decision control preference scale
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 7, 2026, 5:43 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

NCT05060432
View directory record Official record
Conditions
Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
Interventions
EOS-448, pembrolizumab, inupadenant, Dostarlimab, SOC chemotherapies
Drug
Lead sponsor
iTeos Belgium SA
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
San Diego, California • Bergen, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 7, 2026, 5:43 AM EDT
Recruiting Not applicable Interventional

A New Combination of Evidence-Based Interventions to Improve Primary Care Diagnostic Safety and Efficiency

NCT05735314
View directory record Official record
Conditions
Anemia, Decreased Glomerular Filtration Rate
Interventions
Enhanced diagnostic team implementing three evidence-based interventions, Usual care
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 7, 2026, 5:43 AM EDT
Recruiting Phase 2 Interventional

PDT For Induction Therapy For Head And Neck Cancer

NCT07214987
View directory record Official record
Conditions
Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Toripalimab-tpzi, Cisplatin, Docetaxel
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 7, 2026, 5:43 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05287113
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Retifanlimab, INCAGN02385, INCAGN02390, Placebo
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years to 99 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 7, 2026, 5:43 AM EDT
Completed Not applicable Interventional

Collaborative Care for Infants at Risk

NCT03199326
View directory record Official record
Conditions
Child Abuse, Primary Health Care, Child Welfare
Interventions
Collaborative Care
Other
Lead sponsor
University of Utah
Other
Eligibility
0 Days to 364 Days
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 7, 2026, 5:43 AM EDT
Recruiting No phase listed Observational

Outcomes of Health Care Transition for AYA With a Cancer Predisposition

NCT07456904
View directory record Official record
Conditions
Genetic Predisposition
Interventions
Readiness Assessment, Transition Outcomes Survey A, Transition Outcomes Survey B
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 7, 2026, 5:43 AM EDT